SCHEMBL477699

SCHEMBL477699

OC(c1ccccc1)C1CC1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.56
CYP2D6 P10635 2/20 0.56
KDM4E B2RXH2 2/20 0.56
HTR2A P28223 2/20 0.56
CYP3A4 P08684 1/20 0.56
TSHR P16473 1/20 0.56
HTR2C P28335 1/20 0.56
CARM1 Q86X55 1/20 0.53
PRMT6 Q96LA8 1/20 0.53
IDO1 P14902 2/20 0.48
EPHX1 P07099 1/20 0.47
HRH1 P35367 1/20 0.45
LMNA P02545 1/20 0.44
GBA1 P04062 1/20 0.44
HIF1A Q16665 1/20 0.44
STAT3 P40763 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
HSD17B2 P37059 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19645377 1.00 CYP1A2 (0.56) CYP1A2CYP2D6KDM4EHTR2ACYP3A4
SCHEMBL8705439 0.91 KDM4E (0.53) CYP1A2CYP2D6KDM4EHTR2ACYP3A4
SCHEMBL3310267 0.91 CYP1A2 (0.53) CYP1A2CYP2D6KDM4EHTR2ACYP3A4
SCHEMBL15564459 0.89 CYP1A2 (0.49) CYP1A2CYP2D6KDM4EHTR2ACYP3A4
SCHEMBL1430742 0.89 IDO1 (0.53) CYP1A2CYP2D6KDM4EHTR2ACYP3A4
SCHEMBL477415 0.89 IDO1 (0.53) CYP1A2CYP2D6KDM4EHTR2ACYP3A4
SCHEMBL477416 0.89 IDO1 (0.53) CYP1A2CYP2D6KDM4EHTR2ACYP3A4
SCHEMBL16995185 0.89 IDO1 (0.53) CYP1A2CYP2D6KDM4EHTR2ACYP3A4
SCHEMBL4676513 0.85 CYP1A2 (0.49) CYP1A2CYP2D6KDM4EHTR2ACYP3A4
SCHEMBL17840999 0.85 KDM4E (0.49) CYP1A2CYP2D6KDM4EHTR2ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250075147-A1 FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS OSMO LABS, PBC 2025-03-06 US claimed
US-6989052-B1 Phase change ink printing process XEROX CORPORATION (US) 2006-01-24 US claimed
US-20060004123-A1 PHASE CHANGE INK PRINTING PROCESS XEROX CORPORATION 2006-01-05 US claimed
WO-2004111092-A1 MODIFIED ALGINIC ACID OR ALGINIC ACID DERIVATIVES AND THERMOSETTING ANTI-REFLECTIVE COMPOSITIONS THEREOF AZ ELECTRONIC MATERIALS USA CORP. (US) 2004-12-23 WO claimed
US-20040253532-A1 Modified alginic acid of alginic acid derivatives and thermosetting anti-reflective compositions thereof MERCK PATENT GMBH (DE) 2004-12-16 US claimed
JP-62205038-A None JP disclosed
US-20260000642-A1 PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS TAY THERAPEUTICS LTD (GB) 2026-01-01 US disclosed
US-20250263370-A1 PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS Tay Therapeutics Limited (GB) 2025-08-21 US disclosed
EP-4558224-A1 PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS Tay Therapeutics Limited (GB) 2025-05-28 EP disclosed
US-20250075147-A1 FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS OSMO LABS, PBC 2025-03-06 US disclosed
CN-118812335-A Method for preparing aldehyde or ketone by alcohol oxidation 浙江工业大学 2024-10-22 CN disclosed
US-20240293381-A1 Therapeutic Compounds CELGENE QUANTICEL RES INC (US) 2024-09-05 US disclosed
EP-0254195-A2 Photographic silver halide developer compositions and process for forming photographic silver images MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1988-01-27 EP disclosed
US-4693956-A USING A HYDRAZINE, ANTIFOGGING AGENT AND A HYDROXYMETHYLIDYNE-CONTAINING COMPOUND MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1987-09-15 US disclosed
JP-S62205038-A PRODUCTION OF 4-FLUORO-1-BUTENE DERIVATIVE RIKAGAKU KENKYUSHO 1987-09-09 JP disclosed
EP-0182293-A2 Process for high contrast development of photographic elements MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1986-05-28 EP disclosed
US-4529810-A Preparation of optically-active alpha-substituted carboxylic esters and acids SHELL OIL COMPANY (US) 1985-07-16 US disclosed
EP-0041362-A1 1-Olefin polymerization process and catalyst HERCULES INCORPORATED (US) 1981-12-09 EP disclosed
US-4022903-A α-Thienyl and α-substituted thienyl, phenyl and substituted phenyl cyclopropylomethanols useful as biodegradable insecticides and mollusicides ABBOTT LABORATORIES (US) 1977-05-10 US disclosed
US-4022903-A α-Thienyl and α-substituted thienyl, phenyl and substituted phenyl cyclopropylomethanols useful as biodegradable insecticides and mollusicides ABBOTT LABORATORIES (US) 1977-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240293381-A1 Therapeutic Compounds EP300, BRD4, BRD3 CYP1A2 4769/4885CYP2D6 4794/4885KDM4E 93/4885
US-20260000642-A1 PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS BET1, BRD4, PHKB CYP1A2 3117/4885CYP2D6 3645/4885KDM4E 947/4885
US-20250263370-A1 PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS BET1, PHKB, BRD4 CYP1A2 4517/4885CYP2D6 4476/4885KDM4E 309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.